{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:15:32Z","timestamp":1793391332850,"version":"4.5.0"},"reference-count":62,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Chemotherapy-induced thrombocytopenia (CIT) is a common yet underrecognized complication of systemic chemotherapy, particularly in gastrointestinal (GI) cancers. Despite progress in targeted and immune-based therapies, platinum-based and fluoropyrimidine regimens, especially oxaliplatin-containing protocols, remain standard in GI cancer treatment and are linked to high rates of CIT. This complication often leads to treatment delays, dose reductions, and elevated bleeding risk. This review provides a comprehensive overview of the pathophysiology, clinical implications, and management strategies of CIT in GI malignancies. CIT arises from several mechanisms: direct cytotoxicity to megakaryocyte progenitors, disruption of the marrow microenvironment, thrombopoietin dysregulation, and immune-mediated platelet destruction. Platinum agents, antimetabolites, and immune checkpoint inhibitors can contribute to these effects. Oxaliplatin-induced CIT may occur acutely via immune mechanisms or chronically through marrow suppression. CIT affects 20\u201325% of solid tumor patients, with highest rates in those receiving gemcitabine (64%), carboplatin (58%), and oxaliplatin (50%). Within GI cancer regimens, FOLFOXIRI and S-1 plus oxaliplatin show higher CIT incidence compared to FOLFIRI and CAPIRI. Thrombocytopenia is graded by severity, from mild (Grade 1\u20132) to severe (Grade 3\u20134), and often necessitates treatment adjustments, transfusions, or supportive therapies. Current strategies include chemotherapy dose modification, platelet transfusion, and thrombopoietin receptor agonists (TPO-RAs) like romiplostim and eltrombopag. While platelet transfusions help in acute settings, TPO-RAs may preserve dose intensity and reduce bleeding. Emerging agents targeting megakaryopoiesis and marrow protection offer promising avenues for long-term management.<\/jats:p>","DOI":"10.3390\/curroncol32080455","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T15:16:37Z","timestamp":1755184597000},"page":"455","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Understanding Chemotherapy-Induced Thrombocytopenia: Implications for Gastrointestinal Cancer Treatment"],"prefix":"10.3390","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3895-9474","authenticated-orcid":false,"given":"Supriya","family":"Peshin","sequence":"first","affiliation":[{"name":"Norton Community Hospital, Norton, VA 24273, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adit","family":"Dharia","sequence":"additional","affiliation":[{"name":"HCA Florida Healthcare, USF Morsani College of Medicine GME Oak Hill Program, Orlando, FL 32801, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9062-9761","authenticated-orcid":false,"given":"Ehab","family":"Takrori","sequence":"additional","affiliation":[{"name":"College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4507-8157","authenticated-orcid":false,"given":"Jasmeet","family":"Kaur","sequence":"additional","affiliation":[{"name":"Fox Chase Cancer Comprehensive Center, Philadelphia, PA 19111, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kannan","family":"Thanikachalam","sequence":"additional","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center, Buffalo, NY 14203, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renuka","family":"Iyer","sequence":"additional","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center, Buffalo, NY 14203, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,14]]},"reference":[{"key":"ref_1","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/bjh.19797","article-title":"Avatrombopag for the treatment of patients with chemotherapy-induced thrombocytopenia: A case series","volume":"206","author":"Galamaga","year":"2025","journal-title":"Br. J. Haematol."},{"key":"ref_4","unstructured":"Tallent, A. (Oncology News Central, 2025). Romiplostim Effective in Managing CIT in GI Cancers, Oncology News Central."},{"key":"ref_5","unstructured":"Society of Chemotherapy, China Anti-Cancer Association, and Committee of Neoplastic Supportive-Care, China Anti-Cancer Association (2023). Consensus on the clinical diagnosis, treatment and prevention of cancer treatment-induced thrombocytopenia in China (2023 edition). Zhonghua Yi Xue Za Zhi, 103, 2579\u20132590."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s12672-023-00616-3","article-title":"Chemotherapy-induced thrombocytopenia: Literature review","volume":"14","author":"Gao","year":"2023","journal-title":"Discov. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/j.clinthera.2009.11.020","article-title":"Anemia and thrombocytopenia in patients undergoing chemotherapy for solid tumors: A descriptive study of a large outpatient oncology practice database, 2000\u20132007","volume":"31","author":"Wu","year":"2009","journal-title":"Clin. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.2165\/11594310-000000000-00000","article-title":"Thrombocytopenia in Adult Cancer Patients Receiving Cytotoxic Chemotherapy: Results from a Retrospective Hospital-Based Cohort Study","volume":"34","author":"Shantakumar","year":"2011","journal-title":"Drug Saf."},{"key":"ref_9","first-page":"282","article-title":"Managing thrombocytopenia associated with cancer chemotherapy","volume":"29","author":"Kuter","year":"2015","journal-title":"Oncology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1146\/annurev-pathol-012615-044414","article-title":"Hematopoietic Stem Cell Niche in Health and Disease","volume":"11","author":"Hoggatt","year":"2016","journal-title":"Annu. Rev. Pathol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"509","DOI":"10.4103\/0973-1482.154056","article-title":"Oxaliplatin-induced acute thrombocytopenia","volume":"12","author":"Erdem","year":"2016","journal-title":"J. Cancer Res. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.5114\/aoms\/141134","article-title":"Prophylactic administration of recombinant human thrombopoietin attenuates XELOX or SOX regimen-induced thrombocytopaenia","volume":"17","author":"Li","year":"2021","journal-title":"Arch. Med. Sci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1093\/annonc\/mds074","article-title":"Oxaliplatin-related thrombocytopenia","volume":"23","author":"Jardim","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_14","first-page":"944","article-title":"The effects of 5-fluorouracil on hematopoiesis: Studies of murine megakaryocyte-CFC, granulocyte-macrophage-CFC, and peripheral blood cell levels","volume":"11","author":"Yeager","year":"1983","journal-title":"Exp. Hematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.ejca.2011.03.005","article-title":"Haematologic toxicities associated with the addition of bevacizumab in cancer patients","volume":"47","author":"Schutz","year":"2011","journal-title":"Eur. J. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1002\/cam4.5062","article-title":"Hematological toxicities in PARP inhibitors: A real-world study using FDA adverse event reporting system (FAERS) database","volume":"12","author":"Shu","year":"2023","journal-title":"Cancer Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/liv.13317","article-title":"Thrombocytopenia in chronic liver disease","volume":"37","year":"2017","journal-title":"Liver Int."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.3324\/haematol.2021.279512","article-title":"Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic malignancies","volume":"107","author":"Kuter","year":"2022","journal-title":"Haematologica"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/ajh.20516","article-title":"Immune-mediated thrombocytopenia resulting from sensitivity to oxaliplatin","volume":"81","author":"Curtis","year":"2006","journal-title":"Am. J. Hematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/MAJ.0000000000000243","article-title":"Irinotecan-induced immune thrombocytopenia","volume":"347","author":"Mirtsching","year":"2014","journal-title":"Am. J. Med. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1182\/blood.2020009016","article-title":"Hematologic complications of immune checkpoint inhibitors","volume":"139","author":"Kroll","year":"2022","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1093\/annonc\/mdp374","article-title":"Drug-induced thrombocytopenia induced by trastuzumab: A special challenge in a curable disease","volume":"20","year":"2009","journal-title":"Ann. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Zhan, Y., Cheng, X., Mei, P., Tan, S., Feng, W., and Jiang, H. (2024). Safety of first-line systemic therapy in patients with metastatic colorectal cancer: A network meta-analysis of randomized controlled trials. BMC Cancer, 24.","DOI":"10.1186\/s12885-024-12662-3"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12959-016-0095-z","article-title":"Thrombopoietin and its receptor in normal and neoplastic hematopoiesis","volume":"14","author":"Kaushansky","year":"2016","journal-title":"Thromb. J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1200\/JCO.23.00795","article-title":"Gemcitabine and Paclitaxel Versus Gemcitabine Alone After 5-Fluorouracil, Oxaliplatin, and Irinotecan in Metastatic Pancreatic Adenocarcinoma: A Randomized Phase III PRODIGE 65-UCGI 36-GEMPAX UNICANCER Study","volume":"42","author":"Malka","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1182\/asheducation-2018.1.576","article-title":"Drug-associated thrombocytopenia","volume":"2018","author":"Bakchoul","year":"2018","journal-title":"Hematology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1002\/cncr.20290","article-title":"Gemcitabine-associated thrombotic microangiopathy","volume":"100","author":"Humphreys","year":"2004","journal-title":"Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"130","DOI":"10.5414\/CNP71130","article-title":"Gemcitabine nephrotoxicity and hemolytic uremic syndrome: Report of 29 cases from a single institution","volume":"71","author":"Glezerman","year":"2009","journal-title":"Clin. Nephrol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/bcp.13808","article-title":"Thrombotic microangiopathy associated with gemcitabine use: Presentation and outcome in a national French retrospective cohort","volume":"85","author":"Daviet","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_30","first-page":"E30","article-title":"Eculizumab therapy for gemcitabine induced hemolytic uremic syndrome: Case series and concise review","volume":"5","author":"Lohr","year":"2014","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e7429","DOI":"10.1002\/cam4.7429","article-title":"Romiplostim in chemotherapy-induced thrombocytopenia: A review of the literature","volume":"13","author":"Soff","year":"2024","journal-title":"Cancer Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/ejh.13595","article-title":"The incidence of thrombocytopenia in adult patients receiving chemotherapy for solid tumors or hematologic malignancies","volume":"106","author":"Shaw","year":"2021","journal-title":"Eur. J. Haematol."},{"key":"ref_33","unstructured":"Cancer Therapy Evaluation Program, U.S. Department of Health and Human Services (2025, August 04). Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE), Version 3.0, Available online: http:\/\/ctep.cancer.gov."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment","volume":"47","author":"Miller","year":"1981","journal-title":"Cancer"},{"key":"ref_35","first-page":"170","article-title":"Occurrence and Management of Thrombocytopenia in Metastatic Colorectal Cancer Patients Receiving Chemotherapy: Secondary Analysis of Data From Prospective Clinical Trials","volume":"20","author":"Kilpatrick","year":"2021","journal-title":"Clin. Color. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e16334","DOI":"10.1200\/JCO.2023.41.16_suppl.e16334","article-title":"A retrospective study on the efficacy and safety of avatrombopag in the treatment of chemotherapy-induced thrombocytopenia in gastrointestinal cancer","volume":"41","author":"Chen","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"4061","DOI":"10.3748\/wjg.v28.i30.4061","article-title":"Thrombocytopenia in chronic liver disease: Physiopathology and new therapeutic strategies before invasive procedures","volume":"28","author":"Gallo","year":"2022","journal-title":"World J. Gastroenterol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"101139","DOI":"10.1016\/j.blre.2023.101139","article-title":"Optimal management of chemotherapy-induced thrombocytopenia with thrombopoietin receptor agonists","volume":"63","year":"2024","journal-title":"Blood Rev."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1111\/bjh.20037","article-title":"Chemotherapy-induced thrombocytopenia: Modern diagnosis and treatment","volume":"206","author":"Song","year":"2025","journal-title":"Br. J. Haematol."},{"key":"ref_40","unstructured":"National Cancer Institute (NCI) (2017). Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, U.S. Department of Health and Human Services."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/trf.16277","article-title":"What is clinically significant bleeding?","volume":"61","author":"Chai","year":"2021","journal-title":"Transfusion"},{"key":"ref_42","unstructured":"American Association of Blood Banks (AABB) (AABB, 2025). AABB Develops New Platelet Transfusion Guidelines, AABB."},{"key":"ref_43","unstructured":"National Institute for Health and Care Excellence (NICE) (2015). Blood Transfusion. NICE Guideline [NG24]: Recommendations, NICE."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1200\/JCO.18.01931","article-title":"Romiplostim Treatment of Chemotherapy-Induced Thrombocytopenia","volume":"37","author":"Soff","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Cui, Y., He, Y., Hu, C., Tu, C., Huang, J., Zhu, X., Zang, C., Ding, K., Zhan, B., and Zhao, Y. (2022). Avatrombopag for the treatment of thrombocytopenia induced by chemotherapy in patients with solid tumors: A multicenter, open-label, single-arm trial. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.970978"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jtha.2023.09.031","article-title":"Management of chemotherapy-induced thrombocytopenia: Guidance from the ISTH Subcommittee on Hemostasis and Malignancy","volume":"22","author":"Soff","year":"2024","journal-title":"J. Thromb. Haemost."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1007\/s12029-024-01059-x","article-title":"Risk Factors of Chemotherapy-Induced Thrombocytopenia After Oxaliplatin-Containing Chemotherapy for Gastrointestinal Malignancies","volume":"55","author":"Li","year":"2024","journal-title":"J. Gastrointest. Cancer"},{"key":"ref_48","first-page":"482402","article-title":"Romiplostim for chemotherapy-induced thrombocytopenia in colorectal, gastroesophageal, and pancreatic cancers: Results of the global, phase III RECITE trial","volume":"43","author":"Munoz","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s12185-017-2319-9","article-title":"Eltrombopag for thrombocytopenia in patients with advanced solid tumors receiving gemcitabine-based chemotherapy: A randomized, placebo-controlled phase 2 study","volume":"106","author":"Winer","year":"2017","journal-title":"Int. J. Hematol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"17588359241260985","DOI":"10.1177\/17588359241260985","article-title":"Hetrombopag for the management of chemotherapy-induced thrombocytopenia in patients with advanced solid tumors: A multicenter, randomized, double-blind, placebo-controlled, phase II study","volume":"16","author":"Qin","year":"2024","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s00280-014-2416-x","article-title":"The impact of dose\/time modification in irinotecan- and oxaliplatin-based chemotherapies on outcomes in metastatic colorectal cancer","volume":"73","author":"Nakayama","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.2017.76.1734","article-title":"Platelet Transfusion for Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update","volume":"36","author":"Schiffer","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Quillen, K. (2013). Diagnosis and Management of Platelet Alloimmunization. Hematologist, 10.","DOI":"10.1182\/hem.V10.6.1023"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1159\/000151350","article-title":"Reactions Induced by Platelet Transfusions","volume":"35","author":"Kiefel","year":"2008","journal-title":"Transfus. Med. Hemother."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1002\/cam4.856","article-title":"Partial splenic embolization to permit continuation of systemic chemotherapy","volume":"5","author":"Luz","year":"2016","journal-title":"Cancer Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1007\/s00268-009-0095-2","article-title":"Partial Splenic Embolization Versus Splenectomy for the Management of Hypersplenism in Cirrhotic Patients","volume":"33","author":"Amin","year":"2009","journal-title":"World J. Surg."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s12185-013-1382-0","article-title":"The biology of thrombopoietin and thrombopoietin receptor agonists","volume":"98","author":"Kuter","year":"2013","journal-title":"Int. J. Hematol."},{"key":"ref_58","first-page":"1217","article-title":"Romiplostim for management of chemotherapy-induced thrombocytopenia","volume":"22","author":"Parameswaran","year":"2014","journal-title":"Support. Care Cancer"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e179","DOI":"10.1016\/S2352-3026(22)00001-1","article-title":"Avatrombopag for chemotherapy-induced thrombocytopenia in patients with non-haematological malignancies: An international, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Safina","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s00262-021-03068-2","article-title":"Immune checkpoint inhibitor-related thrombocytopenia: Incidence, risk factors and effect on survival","volume":"71","author":"Haddad","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Weycker, D., Hatfield, M., Grossman, A., Hanau, A., Lonshteyn, A., Sharma, A., and Chandler, D. (2019). Risk and consequences of chemotherapy-induced thrombocytopenia in US clinical practice. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-5354-5"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1002\/cncr.11195","article-title":"Cost of chemotherapy-induced thrombocytopenia among patients with lymphoma or solid tumors","volume":"97","author":"Elting","year":"2003","journal-title":"Cancer"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/8\/455\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:27:05Z","timestamp":1760034425000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/8\/455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,14]]},"references-count":62,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["curroncol32080455"],"URL":"https:\/\/doi.org\/10.3390\/curroncol32080455","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,14]]}}}